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Abstract
Background: Direct cellular contact with stimulated T cells is a potent mechanism that induces cytokine production in
human monocytes in the absence of an infectious agent. This mechanism is likely to be relevant to T cell-mediated
inflammatory diseases such as rheumatoid arthritis and multiple sclerosis. Microparticles (MP) generated by stimulated T
cells (MPT) display similar monocyte activating ability to whole T cells, isolated T cell membranes, or solubilized T cell
membranes. We previously demonstrated that high-density lipoproteins (HDL) inhibited T cell contact- and MPT-induced
production of IL-1b but not of its natural inhibitor, the secreted form of IL-1 receptor antagonist (sIL-1Ra).
Methodology/Principal Findings: Labeled MPT were used to assess their interaction with monocytes and T lymphocytes by
flow cytometry. Similarly, interactions of labeled HDL with monocytes and MPT were assessed by flow cytometry. In parallel,
the MPT-induction of IL-1b and sIL-1Ra production in human monocytes and the effect of HDL were assessed in cell cultures.
The results show that MPT, but not MP generated by activated endothelial cells, bond monocytes to trigger cytokine
production. MPT did not bind T cells. The inhibition of IL-1b production by HDL correlated with the inhibition of MPT binding
to monocytes. HDL interacted with MPT rather than with monocytes suggesting that they bound the activating factor(s) of T
cell surface. Furthermore, prototypical pro-inflammatory cytokines and chemokines such as TNF, IL-6, IL-8, CCL3 and CCL4
displayed a pattern of production induced by MPT and inhibition by HDL similar to IL-1b, whereas the production of CCL2,
like that of sIL-1Ra, was not inhibited by HDL.
Conclusions/Significance: HDL inhibit both MPT binding to monocytes and the MPT-induced production of some but not all
cytokines, shedding new light on the mechanism by which HDL display their anti-inflammatory functions.
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Introduction
An unbalanced cytokine homeostasis plays an important part in
the pathogenesis of chronic inflammatory diseases. This suggests
that the mechanisms ruling the production of pro-inflammatory
cytokines, their inhibitors, and inhibitory mechanisms escape
normal controls. IL-1b is a prototypical pro-inflammatory
cytokine whose involvement in immuno-inflammatory diseases
such as multiple sclerosis (MS) and rheumatoid arthritis (RA) is
well established. In the absence of an infectious agent (i.e., in non-
septic conditions), the nature of the factors triggering the
production of the prototypical pro-inflammatory cytokines, TNF
and IL-1b, is still elusive. In chronic inflammatory diseases of
autoimmune etiology, T cells and monocytes/macrophages
infiltrate the target tissue. In animal models of MS and RA, the
transfer of T cells isolated from diseased animals induces the
disease in healthy animals, strongly suggesting that T cells play a
pathogenic role [1,2]. It is now acknowledged that direct cellular
contact with stimulated T cells induces the massive up-regulation
of IL-1 and TNF in human monocytes/macrophages [3–5].
Besides triggering pro-inflammatory cytokine production, contact-
mediated activation of monocytes also induces the production
and/or shedding of cytokine inhibitors such as the secreted form of
IL-1 receptor antagonist (sIL-1Ra), and soluble receptors of IL-1
and TNF [6–9]. Once stimulated, most T cell types, including T
cell clones, freshly isolated T lymphocytes, and T cell lines such as
HUT-78 cells, induce the production of IL-1b and TNF in
monocytes/macrophages [10]. Furthermore, depending on T cell
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11869type and T cell stimulus, direct cellular contact with stimulated T
lymphocytes can induce different patterns of products in
monocytes/macrophages (reviewed in [3,4,11]), suggesting that
multiple ligands and counter-ligands are involved in the contact-
mediated activation of monocytes/macrophages. This premise
strengthened by observations showing that TH1 cell clones
preferentially induce IL-1b rather than sIL-1Ra production, and
cytokine-stimulated T lymphocytes induce TNF production while
failing to trigger that of IL-10 [8,12]. Therefore, cellular contact
with stimulated T cells can induce an imbalance in the production
of pro-inflammatory versus anti-inflammatory cytokines, reflecting
that observed in chronic inflammatory diseases.
By generating microparticles (MP) cells can disseminate cell
surface molecules and thus ensure ‘‘distant’’ cellular contact. MP
are fragments (0.1–1 mm diameter) shed from the plasma
membrane of stimulated or apoptotic cells. Having long been
considered inert debris reflecting cellular activation or damage,
MP are now acknowledged as cellular effectors involved in cell-cell
crosstalk [13]. Indeed, MP display membrane proteins as well as
bioactive lipids implicated in a variety of fundamental processes
and thus constitute a disseminated pool of bioactive effectors [14].
MP are present in the circulation of healthy subjects, and their
numbers increase upon various pathological conditions [15].
Elevated MP have also been reported in chronic inflammatory
diseases [16–18] including RA [19–22] and MS [18,23–26].
Although present in patients’ plasma, MS cerebrospinal fluid has,
to our knowledge, not been investigated for the presence of MP. In
RA synovial fluid, MP are abundant and modulate fibroblast-like
synoviocyte activity in vitro [21,22,27,28]. We recently demon-
strated that MP generated by stimulated T cells can activate
monocytes to produce cytokines similarly to membranes or
solubilized membranes of stimulated T cells [29]. Furthermore,
T cell contact-induced production of IL-1b and TNF in
monocytes is specifically inhibited by high-density lipoproteins
(HDL)-associated apolipoprotein A–I (apo A–I) [30], a ‘‘negative’’
acute-phase protein. HDL may infiltrate the inflamed tissue to
counteract T cell contact-induce monocytes activation [31].
Furthermore, microarray analysis demonstrated that direct
contact with stimulated T cells induces the expression of genes
mostly related to inflammatory pathways but different from those
induced under acute/infectious inflammatory conditions (e.g.,
induced by lipopolysaccharides), and that HDL inhibit the
expression of pro rather than anti-inflammatory molecules [32].
For instance, in contrast to the production of IL-1b, HDL do not
inhibit that of sIL-1Ra [29]. However, the mechanism by which
HDL affect cytokine production in monocytes is still elusive. In this
study we used MP to assess their interaction with monocytes and
the effects of HDL. The results show that MP generated by
stimulated T cells bind monocytes but not T lymphocytes and that
HDL inhibit the interaction of MPT with monocytes. Therefore,
HDL may inhibit cytokine production in human monocytes by
interfering with the binding of the activating factor(s) at the surface
of stimulated T cells to receptor(s) at the surface of monocytes.
Results
Characterization of microparticles generated by
stimulated HUT-78 cells (MPT)
We previously demonstrated that MP generated by stimulated
HUT-78 cells (here referred to as MPT) display similar monocyte
activating ability to MP generated by stimulated blood T
lymphocytes [29]. In the present study we used MPT to avoid
variations often observed between T lymphocytes from different
blood donors. Prior to assessing the ability of MPT to activate
human monocytes, we determined their physicochemical char-
acteristics. As demonstrated by electron microscopy, MPT are
round particles with heterogeneous sizes displaying diameters
between 0.1 and 0.8 mm, although most of MPT were of small
size (Fig. 1A). Flow cytometry analysis of MPT preparation shows
that particles between 0.1 and 0.8 mm bound annexin V (Fig. 1B)
demonstrating that phosphatidylserine was exposed at their
surface, thus defining them as microparticles. To assess the
quality of MPT preparations, we tested their ability to activate IL-
1b and sIL-1Ra production in isolated monocytes. As previously
described [29], MP isolated from unstimulated HUT-78 cells did
not affect the production of cytokines in human monocytes (data
not shown). We previously determined that the production of
both IL-1b and sIL-1Ra was induced in a dose-response manner
by MPT, the production of sIL-1Ra reaching a plateau at 1 mg/
ml proteins of MPT while that of IL-1b was still increasing at
6 mg/ml proteins of MPT [29]. Here we used an intermediate
dose, 3 mg/ml proteins of MPT, which induced the production of
both IL-1b and sIL-1Ra in monocytes (Fig. 1C). MPT-induced
IL-1b production was inhibited in the presence of 0.2 mg/ml
HDL, i.e., a concentration that was determined to be optimal
[30]. In contrast, sIL-1Ra production was not significantly
affected by HDL, suggesting that different pathways or surface
molecules were involved in the induction of the latter molecules.
These results demonstrate that MPT were able to activate
monocytes and confirmed previous results suggesting that HDL
inhibited only a part of factors induced by contact with stimulated
T cells or MPT [29,32].
MPT specifically bind and activate human monocytes
Since direct cellular contact with stimulated T cells is
required to induce cytokine production in monocytes [33], we
Figure 1. Characterization of microparticles generated by
stimulated HUT-78 cells (MPT). (A) Scanning electron microscopy
of isolated MPT. Scale bar =500 nm. (B) Flow cytometry analysis of the
binding of FITC-annexin V to MPT. (C) Monocytes (5610
4 cells/200 ml/
well; 96-well plates) were activated by MPT (3 mg/ml) for 24 h in the
presence (empty columns) or absence (grey columns) of HDL (0.2 mg/
ml proteins). Cell culture supernatants were measured for the presence
of the indicated cytokines. Results are expressed as mean 6 SD of 3
experiments carried out with monocytes isolated from 3 individual
donors. ** p,0.01, as determined by paired student t test.
doi:10.1371/journal.pone.0011869.g001
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monocytes. To this aim, we assessed the binding of green
PKH67-labelled MPT to CD14
+ monocytes by flow cytometry.
Al a r g ep a r to fC D 1 4
+ monocytes (62.7%) bound MPT (Fig. 2A).
Non-specific MPT binding to or fusion with target cell
membranes was ruled out since MPT did not bind CD3
+ cells,
i.e.,l y m p h o c y t e s( F i g .2 B ) .T h i ss u g g e s t st h a tM P T specifically
interacted with monocytes. Furthermore, MP isolated from
supernatants of unstimulated HUT-78 cells did not bind to
CD14
+ monocytes (data not shown), further suggesting that the
binding of MPT to monocytes occurred through molecules
expressed at the surface of stimulated T cells but not on
unstimulated cells. A fraction of CD14
+ monocytes (21.4%)
bound MP from TNF-activated endothelial cells but were not
induced to produce IL-1b (Figs. 2C and 2D). Indeed, only MPT
triggered the production of IL-1b in human monocytes, whereas
MP generated from activated platelets or endothelial cells were
inefficient, even at concentrations 4- to 5-fold higher than that
of MPT (Fig. 2D). Together these results suggest that only MPT
were able to bind and activate monocytes to produce IL-1b.
HDL inhibit MPT interactions with human monocytes
Because HDL inhibited IL-1b production in MPT-activated
monocytes, we assessed whether they would interfere with MPT
binding to monocytes. As shown in Fig. 3A, the binding of MPT
(12 mg/ml) to monocytes was inhibited in the presence of 0.2 mg/
ml HDL. The binding of PKH67-labelled MPT was dose-
dependent and reached a plateau between 12 and 24 mg/ml
protein, i.e., around 1610
6 MP/ml (Fig. 3B). HDL inhibited the
binding of MPT to monocytes by 30612% between 3 and 24 mg/
ml MPT (Fig. 3B). This observation suggests that HDL inhibit IL-
1b production by interfering with the binding of the activating
factor to its receptor on monocytes.
HDL bind MPT
To determine whether HDL interacted with the activating
factor on MPT or to its monocytic receptor, the binding of FITC-
HDL to monocytes and MP from both stimulated and resting
HUT-78 cells was assessed by flow cytometry. FITC-HDL bound
CD14
+ monocytes to some extent, a small enhancement of
fluorescence intensity being observed (Fig. 4A), confirming
previous results [30]. In contrast, FITC-HDL bound MPT to a
great extent (Fig. 4B) suggesting that HDL might inhibit monocyte
activation by primarily interacting with the activating factor(s) at
the surface of MPT, i.e., at the surface of stimulated T cells.
Interestingly, FITC-HDL only slightly interacted with MP isolated
from unstimulated T cells (Fig. 4C), indicating that HDL bound to
molecules that were only expressed on stimulated T cells.
Together these results show that HDL are likely to inhibit the
production of cytokines in monocytes activated by MPT by
competing with the monocyte receptor(s) for binding the activating
factor.
Figure 2. MPT specifically bind and activate human monocytes. (A–C) The binding of PKH67-labelled MP from different cellular sources to
isolated human monocytes and T lymphocytes was assessed by flow cytometry. Binding of MPT (12 mg/ml) to CD14
+ monocytes (A) and CD3
+ T
lymphocytes (B). (C) Binding of endothelial cell MP (MPEC;1 2mg/ml) to CD14
+ monocytes. (D) Monocytes (5610
4 cells/well/200 ml/well; 96-well plates)
were activated by 3 mg/ml MPT,1 4mg/ml activated endothelial cells (MPEC) and 14 mg/ml activated platelets (PMP) in the presence (empty columns)
or absence (grey columns) of 0.2 mg/ml HDL. IL-1b was measured in culture supernatants after 24 h incubation. Results are expressed as mean 6 SD
of triplicates.
doi:10.1371/journal.pone.0011869.g002
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production in human monocytes
HDL are not a general inhibitor of T cell contact-activation of
human monocytes [32]. Indeed, HDL preferentially inhibited the
expression of factors with a pro-inflammatory profile, as
exemplified by IL-1b, in the present study, whilst they did not
affect the expression of anti-inflammatory factors, exemplified here
by sIL-1Ra. To extend this observation to the effect of HDL on
MPT-induced cytokine production in human monocytes, we
assessed the effects of HDL on a range of cytokines and
chemokines induced by MPT in human monocytes. As shown in
Fig. 5, in addition to that of IL-1b and sIL-1Ra, MPT induced the
Figure 3. HDL inhibit the binding of MPT to human monocytes. The binding of PKH67-labelled MPT to CD14
+ monocytes in the presence or
absence of HDL was measured by flow cytometry. (A) Representative binding of PKH67-labelled MPT (12 mg/ml proteins) to CD14
+ monocytes in the
presence or absence of 0.2 mg/ml HDL (as indicated). (B) Flow cytometry measurement of the binding of increasing concentration of PKH67-labelled
MPT to CD14
+ monocytes in the absence (closed circles) or presence (empty circles) of 0.2 mg/ml HDL. The percentage 6 SD of MPT
+CD14
+
monocytes (upper right panel) in 3 different experiments is presented.
doi:10.1371/journal.pone.0011869.g003
Figure 4. HDL interaction with MPT. The binding of FITC-HDL to monocytes (A), MPT (B) and MP from unstimulated HUT-78 cells (C) was analyzed
by flow cytometry. Results are representative of 3 different experiments.
doi:10.1371/journal.pone.0011869.g004
HDL Block MPT-Monocyte Binding
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and IL-6, and the chemokines IL-8, CCL2, CCL3 and CCL4.
The production of pro-inflammatory cytokines was inhibited in the
presence of HDL (Fig. 5A) suggesting that they were induced by a
similar activating factor as the one inducing IL-1b production.
This was also true for chemokines (Fig. 5B), with the exception of
CCL2 (Fig. 5C), whose production was not affected by HDL
similarly to that of sIL-1Ra. By comparison with results obtained
in monocytes activated by CEsHUT [32], the present data
demonstrate that MPT indeed displayed similar activity as soluble
extracts of membranes isolated from stimulated HUT-78 cells, i.e.,
CEsHUT. Furthermore they strengthen results of Fig. 4 demon-
strating that different surface molecules were involved in monocyte
activation, part of them being inhibited through interaction with
HDL.
Discussion
This study reveals that MPT specifically interact with monocytes
to trigger cytokine and chemokine production. MPT-monocyte
interaction is inhibited by HDL which are likely to bind the
activating factor(s) on MPT, in turn inhibiting pro-inflammatory
cytokine and chemokine production in monocytes. Interestingly,
the production of sIL-1Ra and CCL2 was not inhibited in the
presence of HDL confirming previous results [29,32] and
suggesting that different factors at the surface of stimulated T
cells and MPT are involved in the induction of pro- and anti-
inflammatory factors in monocytes.
Although studies showed that MP from endothelial cells and
platelets could induce the expression of adhesion molecules and
tissue factor-dependent procoagulant activity in the monocytic cell
line THP-1 [34,35], activation of freshly isolated monocytes is not
a general characteristic of MP in terms of induction of cytokine
production. Indeed, MP generated by activated endothelial cells
and platelets do not induce IL-1b production in monocytes.
However, a small percentage of monocytes do bind MP from
endothelial cells, demonstrating that MP interaction with mono-
cytes is not exclusively due to interactions between activating
factors at the surface of MPT and receptors/counter-ligands on
monocytes, but may occur through adhesion molecules likely to be
present on the surface of all MP as demonstrated in MP generated
by endothelial cells and neutrophils [36,37]. This suggests that the
binding of MP to target cells may occur through multiple ligands
and counter-ligands. It is likely to be the case for MPT, since only
part of their binding to monocytes is inhibited in the presence of
HDL indicating that interactions occur through ligands different
from the IL-1b activating factor(s). Partial inhibition of MPT
binding to monocytes by HDL is also reflected by the inhibition of
the production of a part of cytokines and chemokines induced by
MPT (see Fig. 5), suggesting the involvement of activating factors
which do not bind and therefore are not inhibited by HDL as
exemplified by sIL-1Ra and CCL2 in the present study.
HDL do not represent a universal inhibitor of monocyte
activation since they inhibit the production of only particular
factors induced by contact with MPT. Indeed, among the cytokines
and chemokines which production is induced in monocytes upon
Figure 5. Modulation of cytokine production by HDL in MPT-activated monocytes. Monocytes (5610
4 cells/200 ml/well; 96-well plates)
were activated by MPT (6 mg/ml) for 24 h in the presence (empty columns) or absence (grey columns) of HDL (0.2 mg/ml proteins). Cell culture
supernatants were measured for the presence of the indicated cytokines. Results are expressed as mean 6 SD of 3 experiments carried out with
monocytes isolated from 3 individual donors. * p,0.05; ** p,0.01, as determined by paired student t test.
doi:10.1371/journal.pone.0011869.g005
HDL Block MPT-Monocyte Binding
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These results are reminiscent of previous data showing that the
production of sIL-1Ra, CCL2, and other factors that mainly
display anti-inflammatory functions, is not inhibited by HDL upon
activation by CEsHUT [32]. Indeed, HDL mainly inhibit pro-
inflammatory pathways induced by contact with stimulated T
cells. CCL2 which is a major monocyte chemoattractant is far to
be a prototypical pro-inflammatory factor. Indeed, CCL2
influences T cell immunity in that it induces a bias towards TH2
polarization [38]. Because chronic inflammatory diseases such as
MS and RA in which T cell contact is likely to play a pathogenic
part are mediated by TH1 and TH17, the production of CCL2 by
monocytes/macrophages might be considered as an attempt to
revert T cell polarization to a less inflammatory phenotype [39].
Besides, the premise that the activation of cytokine production by
CEsHUT and MPT is similarly inhibited by HDL, confirms that
MPT and stimulated T cells exhibit similar surface molecules. In
agreement with this observation, multiple studies have shown that
MP express similar surface proteins to the cell they originate from
(reviewed in [40]). Since HDL bind activating factor(s) at the
surface of stimulated T cells and MPT, it is likely that different
molecules on T cells activate monocytes to secrete cytokines and
chemokines; the activity of some/one of them being inhibited by
HDL.
In conclusion, this study demonstrates that stimulated T cells
and MPT express surface factor(s) that bind monocytes and in turn
induce cytokine production. Both MPT binding and the MPT-
induced production of some but not all cytokines are inhibited by
HDL, suggesting that different factors at the surface of T cells and
MPT trigger the production of cytokines. Although the identity of
the activating factors remains elusive, the premise that it displays
tight interactions with monocytes and HDL may provides clues as
to its identification.
Materials and Methods
Ethics statement
Buffy coats of blood of healthy donors were provided by the
Geneva Hospital Blood Transfusion Center. In accordance with
the ethical committee of the Geneva Hospital, the blood bank
obtained informed consent from the donors, who are thus
informed that part of their blood will be used for research
purposes.
Materials
Fetal calf serum (FCS), streptomycin, penicillin, L-glutamine,
RPMI-1640 and PBS free of Ca
2+ and Mg
2+ (Gibco, Paisley,
Scotland); purified phytohaemagglutinin (PHA) (EY Laboratories,
San Marco, CA); Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden); phorbol myristate acetate (PMA), phenylmethylsulfonyl
fluoride (PMSF), polymyxin B sulfate, amphiphilic cell linker dye
kit (PKH67), calcium ionophore A23187, human TNF, and
bovine serum albumin (Sigma Chemicals Co., St. Louis, MO); and
annexin V-FITC, PE-labeled anti-human CD14, and anti-human
CD3 (BD Biosciences) were purchased from the designated
suppliers. Other reagents were of analytical grade or better.
Blood monocytes and T lymphocytes
Peripheral blood monocytes and T lymphocytes were isolated
from buffy coats of blood of healthy volunteers as previously
described [30]. In order to avoid activation by endotoxin,
polymyxin B (2 mg/ml) was added to all solutions during the
monocyte isolation procedure.
T cell stimulation and Isolation and labeling of
microparticles (MP)
T h eh u m a nTc e l ll i n eH U T - 7 8w a sp u r c h a s e df r o mt h e
ATCC (Rockville, MD). Cells were maintained in RPMI-1640
medium supplemented with 10% heat-inactivated FCS, 50 mg/
ml streptomycin, 50 U/ml penicillin and 2 mM L-glutamine in
5% CO2-air humidified atmosphere at 37uC. HUT-78 cells
(2610
6 cells/ml) were stimulated for 6 h with PHA (1 mg/ml)
and PMA (5 ng/ml) as previously described [41,42]. MP were
isolated from culture supernatants of HUT-78 cells as previously
described [29]. MP isolated from supernatants of stimulated
HUT-78 cells were referred to as MPT.A sp r e v i o u s l y
demonstrated, MPT display similar cytokine induction ability
as MP generated by stimulated T lymphocytes isolated from
human blood [29]. Total RNA in MPT reached 35.2617.5 mg/
mg proteins, i.e., 0.760.4 mgR N A / 1 0
6 MPT. This suggests that
MPT were indeed closed vesicles able to protect RNA from
degradation by RNases. IL-1b and sIL-1Ra were not detected in
MPT or MP from unstimulated HUT-78 cells. DNA was below
the detection limit, thus amounting to ,3n g / m gp r o t e i n si n
MPT, suggesting that no or few apoptotic bodies were present
amongst MPT. Alternatively, MP were isolated from culture
supernatants of human brain endothelial cells activated with
TNF (MPEC) and human blood platelets activated with the
ionophore A23187 (PMP) as described previously [16,43].
Isolated MP were counted and their protein content measured
as described [29]. MP preparations contained 19.764.2 mg
proteins/10
6 MP independently of the cellular origin confirming
previous results [29]. MP were lab e l e dw i t hag r e e nf l u o r e s c e n t
amphiphilic cell linker dye kit (PKH67, Sigma) as described
elsewhere [43].
Scanning electron microscopy (SEM)
MPT were centrifuged (20,000 g, for 45 min) and the pellet
fixed with 2% glutaraldehyde (Sigma) in 0.1 M sodium cacodylate,
pH 7.4. The fixed MPT were treated with 1% osmium tetroxide
(Sigma) in 0.1 M cacodylate buffer prior to dehydration in
increasing concentrations of ethanol (30 to 100%). MPT were then
critical-point dried, sputter-coated with gold, and observed under
a Cambridge Stereoscan 260 scanning electron microscope.
Isolation, labeling and immobilization of HDL
Human serum HDL were isolated according to Havel et al.
[44]. When required, HDL were labeled with fluorescein
isothiocyanate (FITC-HDL) as previously described [30]. The
binding of FITC-HDL to cells and MPT was analyzed by direct
flow cytometry on a flow cytometer (FACSCalibur, BD) as
previously described [30].
Cytokine production and measurement
Monocytes (5610
4 cells/well/200 ml) were activated with the
indicated stimulus in RPMI 1640 medium supplemented with
10% heat-inactivated FCS, 50 mg/ml streptomycin, 50 U/ml
penicillin, 2 mM L-glutamine and 5 mg/ml polymyxin B sulfate
(medium) in 96 well plates and cultured for 24 h unless stated
otherwise. When required, monocytes (2610
6 cells/well/1 ml)
were pre-activated by MPT (6 mg/ml) in 24-well Ultra Low
Attachment plates (Corning). After the indicated time, cells were
harvested, washed in PBS and then activated as described above.
The production of cytokines was measured in culture supernatants
by commercially available enzyme immunoassay: IL-1b (Beckman
Coulter Inc.), other cytokines and chemokines (Quantikine, R&D,
Minneapolis, MN).
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Monocytes or T lymphocytes (2610
5 cells/well/200 ml) were
incubated for 3 h at 37uC with the indicated concentration of
PKH67-labelled MP in round bottom polypropylene 96-well
plates. After washing with PBS containing 2% heat inactivated
human AB serum, 1% BSA and 0.1% NaN3, cells were incubated
with PE-labeled anti-human CD14 (monocytes) or anti-human
CD3 (T lymphocytes) antibodies for 20 min. After thorough
washing, cells were analyzed by flow cytometry (FACSCalibur,
BD). Buffers used for flow cytometry analysis were subjected to
filtration (Stericup 0.22 mm, Millipore) to discard interferences
with small debris.
Statistics
When required, significance of differences between groups was
evaluated using Student’s paired t test.
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